Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Physiomics (PYC) Share Price

Intraday
Historical

Price	0.46p on 23-06-2025 at 18:05:09
Change	-0.04p -8%
Buy	0.47p
Sell	0.45p
Buy / Sell PYC Shares

Last Trade:	Buy 1,003,435.00 at 0.466p
Day's Volume:	4,192,026
Last Close:	0.46p
Open:	0.50p
ISIN:	GB00BDR6W943

Day's Range	0.46p - 0.50p
52wk Range:	0.39p - 1.325p
Market Capitalisation:	£1m
VWAP:	0.458011p
Shares in Issue:	303m

Sector: Medical Services

Listed In: FTSE AIM All-Share,

Buy/Sell	Volume	Trade Prc	Trade Type	Trade Time
Physiomics (PYC) Latest Trades
Buy*	1,003,435	0.466p	Ordinary	16:25:28 - 23-Jun-25
Buy*	50,000	0.466p	Ordinary	15:40:53 - 23-Jun-25
Buy*	211,000	0.466p	Ordinary	13:53:56 - 23-Jun-25
Sell*	100,000	0.451p	Ordinary	12:40:13 - 23-Jun-25
Sell*	81,676	0.4506p	Ordinary	12:36:09 - 23-Jun-25
Sell*	39,292	0.4535p	Ordinary	11:11:52 - 23-Jun-25
Sell*	588,269	0.45p	Ordinary	11:03:20 - 23-Jun-25
Sell*	500,000	0.451p	Ordinary	10:08:00 - 23-Jun-25
Sell*	205,231	0.451p	Ordinary	10:07:29 - 23-Jun-25
Sell*	500,000	0.457p	Ordinary	10:07:24 - 23-Jun-25

See more Physiomics trades

Physiomics (PYC) Share Price History
Time period: to
Date	Open	High	Low	Close	Volume
23rd Jun 2025 (Mon)	0.50	0.50	0.46	0.46	4,192,026
20th Jun 2025 (Fri)	0.50	0.50	0.50	0.50	3,359,039
19th Jun 2025 (Thu)	0.50	0.50	0.50	0.50	788,480
18th Jun 2025 (Wed)	0.50	0.50	0.50	0.50	1,824,772
17th Jun 2025 (Tue)	0.50	0.50	0.50	0.50	3,356,343
16th Jun 2025 (Mon)	0.495	0.515	0.49	0.50	9,128,082
13th Jun 2025 (Fri)	0.45	0.46	0.45	0.46	645,557
12th Jun 2025 (Thu)	0.455	0.455	0.44	0.45	2,512,882
11th Jun 2025 (Wed)	0.46	0.46	0.455	0.455	920,701
10th Jun 2025 (Tue)	0.475	0.475	0.425	0.46	13,222,838
9th Jun 2025 (Mon)	0.475	0.475	0.475	0.475	2,400,000
6th Jun 2025 (Fri)	0.47	0.475	0.46	0.475	3,199,207
5th Jun 2025 (Thu)	0.515	0.52	0.47	0.47	10,741,932
4th Jun 2025 (Wed)	0.46	0.585	0.46	0.515	57,036,074
3rd Jun 2025 (Tue)	0.415	0.525	0.415	0.46	56,169,497
2nd Jun 2025 (Mon)	0.405	0.415	0.405	0.415	7,846,707
30th May 2025 (Fri)	0.415	0.415	0.405	0.405	3,848,958
29th May 2025 (Thu)	0.425	0.425	0.415	0.415	7,222,568
28th May 2025 (Wed)	0.405	0.405	0.405	0.405	1,998,209
27th May 2025 (Tue)	0.42	0.42	0.405	0.405	6,295,747
26th May 2025 (Mon)	0.41	0.41	0.41	0.41	0

See more Physiomics price history

Date	Source	Headline
Physiomics (PYC) Regulatory News
16th Jun 2025 7:00 am	RNS	New Head of Biometrics and Two Contracts Awarded
29th May 2025 7:00 am	RNS	Physiomics Awarded Contract Extension
9th May 2025 7:00 am	RNS	Contract Award with New UK Client
7th May 2025 4:45 pm	RNS	AIM Rule 17 and Schedule 2(g) Update
17th Apr 2025 7:00 am	RNS-R	Physiomics Awarded New Contract
16th Apr 2025 7:00 am	RNS-R	Publication of Peer Reviewed Article
15th Apr 2025 7:00 am	RNS-R	Contract Award
17th Mar 2025 7:00 am	RNS	Contract Award with new client
13th Mar 2025 7:00 am	RNS-R	IMC Presentation on Company Website
6th Mar 2025 7:00 am	RNS	Interim Results

See more Physiomics regulatory news

Physiomics (PYC) Share News

AIM WINNERS & LOSERS: Physiomics wins first ever Biometrics deals

16th Jun 2025 10:17

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Monday. Read More

Physiomics wins clinical development contract with new UK client

9th May 2025 13:06

(Alliance News) - Physiomics PLC on Friday said it has won a contract with a new client in the UK. Read More

Physiomics extends long-term collaboration with Numab via new contract

15th Apr 2025 18:23

(Alliance News) - Physiomics PLC on Tuesday said it has secured a new contract with long-standing client Numab Therapeutics AG, a Swiss clinical stage biotech company focused on the development of multi-specific antibodies in immunology and oncology. Read More

IN BRIEF: Physiomics secures GBP102,000 model development contract

17th Mar 2025 16:22

Physiomics PLC - Oxfordshire, England-based mathematical modelling company that supports oncology drug development - Secures contract worth GBP102,000 with a new UK-based biotech firm that is focused on developing antibody drug conjugates based therapies targeting difficult-to-treat cancers. Says the contract will see it develop a pharmacokinetic pharmacodynamic model to inform optimal dosing for the client's upcoming first-in-human trial. Expects the project to run from April until August this year. Chief Executive Peter Sargent says: "We are delighted to be awarded this contract. Not only is this contract with a brand new client, but is also in the area of ADCs; a hot new area of oncology treatments." Read More

IN BRIEF: Physiomics eyes new contracts but half-year loss widens

6th Mar 2025 19:08

Physiomics PLC - Oxfordshire, England-based mathematical modelling company that supports oncology drug development - Pretax loss widens to GBP249,000 in the six months to December 31 compared with GBP235,000 a year prior as revenue dips 12% to GBP329,000 from GBP374,000. Highlights strong pipeline with four contracts won in the first half of the financial year. Based on these signed contracts, the company expects total income for the current financial year will be in line with market expectations, with additional contracted revenue projected into next year - year to June 2026. The company is "actively progressing" a number of late-stage opportunities, however, there is no guarantee that these contracts will be signed within the current financial year. Read More

See more Physiomics news

FTSE 100 Latest

Value8,758.04

Change-16.61

Physiomics (PYC) Share Price

Login to your account